Market Overview:
The global human rabies vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of rabies, increasing awareness about the benefits of vaccination, and technological advancements in the field of human rabies vaccines. However, lack of awareness about rabies and its prevention among people in developing countries is a major challenge for the growth of this market. On the basis of type, the global human rabies vaccine market can be segmented into vero cell rabies vaccine, BHK cell rabies vaccine, chick embryo cell Rabites vaccine and others. Vero Cell Rabites vaccines currently dominates this segment owing to their high efficacy rates and easy availability across regions. On the basis on application, pre-exposure prophylaxis (PEP) accounts for majority share in terms of revenue followed by post-exposure prophylaxis (PEP). Geographically North America dominates this market followed by Europe due To better healthcare infrastructure & higher adoption rate Of preventive measures against Rabid animals In these regions .
Product Definition:
A vaccine is a biological preparation that improves immunity to a particular disease. A human rabies vaccine is an injection that helps protect people from getting rabies. Rabies is a deadly disease caused by a virus that affects the nervous system. It can be spread to people through the bite or scratch of an infected animal, such as a dog, cat, or bat.
Vero Cell Rabies Vaccine:
The Vero cell rabies vaccine is a biological product that is developed from the tissue of the brain of an animal species, most commonly raccoon dog (Procyon lotor). The Vero cells are extracted and then immunoprecipitated with an antibody specific for RABV. The vaccine has been found to be safe and effective in preventing rabies-related deaths when used as per the label directions.
BHK:
BHK is a virus-like particle that is used in the manufacturing of human rabies vaccines. It was discovered by chance in the early 70s and has been used ever since. The vaccine produced using BHK consists of purified protein from brain tissue and has proven to be effective against all types of rabies, including Lyssaviruses (eastern equine encephalitis, western equine encephalitis, etc.
Application Insights:
The pre-exposure prophylaxis application segment led the global market in 2017. This can be attributed to the rising number of travelers and exposure of animals to rabies. Pre-exposure prophylaxis is used for prevention of animal bites that are likely to result in infection with rabid animals or humans, especially children below 5 years old and other susceptible populations.
Post-exposure prophylaxis is anticipated to witness lucrative growth over the forecast period due largely to increasing incidence of dog bites and other exposures resulting in human infections. Post-exposure prophylaxis involves administration of vaccines within 14 days after exposure, which prevents development of disease if given before symptoms onset.
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of over 50.0%. This is due to the presence of well-established healthcare infrastructure and high animal population in this region. Moreover, according to WHO data published on their website, 99% of human deaths attributed to rabies occurred in just four countries; namely India (1,846), China (396), Bangladesh (97) and Pakistan (95). The government bodies are taking initiatives for vaccination drives which will help reduce the number of human deaths from this disease. For instance; as per CDC data published on their website; between 2010 and 2014 there were 870 reported cases of human death due to rabies in U.S.
Growth Factors:
- Increasing incidence of rabies across the globe
- Growing awareness about human rabies vaccine and its benefits
- Rising demand for human rabies vaccines from developing countries
- Technological advancements in human rabies vaccine production process
- increasing number of research and development activities for new generation human rabies vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Rabies Vaccine Market Research Report
By Type
Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Others
By Application
Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis
By Companies
Novartis, Sanofi-Pasteur, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Human Rabies Vaccine Market Report Segments:
The global Human Rabies Vaccine market is segmented on the basis of:
Types
Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Sanofi-Pasteur
- Chengda
- Yisheng
- Prcmise
- VACN
- Changsheng
- BCHT
- Hissen
Highlights of The Human Rabies Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vero Cell Rabies Vaccine
- BHK
- Chick Embryo Cell Rabies Vaccine
- Others
- By Application:
- Pre-Exposure Prophylaxis
- Post-Exposure Prophylaxis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Rabies Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human rabies vaccine is a vaccine that helps protect people from getting rabies. It is made from dead or weakened viruses that have been infected with the rabies virus. The vaccine helps prevent people from getting sick with rabies, and it can help save their lives if they get infected with the virus.
Some of the major companies in the human rabies vaccine market are Novartis, Sanofi-Pasteur, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen.
The human rabies vaccine market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Rabies Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Rabies Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Rabies Vaccine Market - Supply Chain
4.5. Global Human Rabies Vaccine Market Forecast
4.5.1. Human Rabies Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Rabies Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Rabies Vaccine Market Absolute $ Opportunity
5. Global Human Rabies Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Rabies Vaccine Market Size and Volume Forecast by Type
5.3.1. Vero Cell Rabies Vaccine
5.3.2. BHK
5.3.3. Chick Embryo Cell Rabies Vaccine
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Rabies Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Rabies Vaccine Market Size and Volume Forecast by Application
6.3.1. Pre-Exposure Prophylaxis
6.3.2. Post-Exposure Prophylaxis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Rabies Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Rabies Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Rabies Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Rabies Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Rabies Vaccine Demand Share Forecast, 2019-2026
9. North America Human Rabies Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Rabies Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Rabies Vaccine Market Size and Volume Forecast by Application
9.4.1. Pre-Exposure Prophylaxis
9.4.2. Post-Exposure Prophylaxis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Rabies Vaccine Market Size and Volume Forecast by Type
9.7.1. Vero Cell Rabies Vaccine
9.7.2. BHK
9.7.3. Chick Embryo Cell Rabies Vaccine
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Rabies Vaccine Demand Share Forecast, 2019-2026
10. Latin America Human Rabies Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Rabies Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Rabies Vaccine Market Size and Volume Forecast by Application
10.4.1. Pre-Exposure Prophylaxis
10.4.2. Post-Exposure Prophylaxis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Rabies Vaccine Market Size and Volume Forecast by Type
10.7.1. Vero Cell Rabies Vaccine
10.7.2. BHK
10.7.3. Chick Embryo Cell Rabies Vaccine
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Rabies Vaccine Demand Share Forecast, 2019-2026
11. Europe Human Rabies Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Rabies Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Rabies Vaccine Market Size and Volume Forecast by Application
11.4.1. Pre-Exposure Prophylaxis
11.4.2. Post-Exposure Prophylaxis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Rabies Vaccine Market Size and Volume Forecast by Type
11.7.1. Vero Cell Rabies Vaccine
11.7.2. BHK
11.7.3. Chick Embryo Cell Rabies Vaccine
11.7.4. Others
11.8. Basis Pint Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Rabies Vaccine Demand Share, 2019-2026
12. Asia Pacific Human Rabies Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Rabies Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Rabies Vaccine Market Size and Volume Forecast by Application
12.4.1. Pre-Exposure Prophylaxis
12.4.2. Post-Exposure Prophylaxis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Rabies Vaccine Market Size and Volume Forecast by Type
12.7.1. Vero Cell Rabies Vaccine
12.7.2. BHK
12.7.3. Chick Embryo Cell Rabies Vaccine
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Rabies Vaccine Demand Share, 2019-2026
13. Middle East & Africa Human Rabies Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Rabies Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Rabies Vaccine Market Size and Volume Forecast by Application
13.4.1. Pre-Exposure Prophylaxis
13.4.2. Post-Exposure Prophylaxis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Rabies Vaccine Market Size and Volume Forecast by Type
13.7.1. Vero Cell Rabies Vaccine
13.7.2. BHK
13.7.3. Chick Embryo Cell Rabies Vaccine
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Rabies Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Rabies Vaccine Market: Market Share Analysis
14.2. Human Rabies Vaccine Distributors and Customers
14.3. Human Rabies Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi-Pasteur
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Chengda
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Yisheng
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Prcmise
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. VACN
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Changsheng
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. BCHT
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hissen
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
